{
  "source": "PA-Med-Nec-Livdelzi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 2356-1\nProgram Prior Authorization/Medical Necessity\nMedication Livdelzi® (seladelpar)\nP&T Approval Date 12/2024\nEffective Date 3/1/2025\n1. Background:\nLivdelzi (seladelpar) is a peroxisome proliferator-activated receptor (PPAR)-delta agonist\nindicated for the treatment of primary biliary cholangitis (PBC) in combination with\nursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as\nmonotherapy in patients unable to tolerate UDCA.\nThis indication is approved under accelerated approval based on a reduction of alkaline\nphosphatase (ALP). Improvement in survival or prevention of liver decompensation events have\nnot been demonstrated. Continued approval for this indication may be contingent upon\nverification and description of clinical benefit in confirmatory trial(s).1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Livdelzi will be approved based on all of the following criteria:\na. Diagnosis of primary biliary cholangitis\n-AND-\nb. Patient does not have decompensated cirrhosis\n-AND-\nc. One of the following^:\n(1) Both of the following:\n(a) Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)\n(b) Patient has failed to achieve an alkaline phosphatase (ALP) level of less than\n1.67 times the upper limit of normal after at least 12 consecutive months of\ntreatment with ursodeoxycholic acid (e.g., Urso, ursodiol)\n-OR-\n(2) History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso,\nursodiol)\n-AND-\n© 2024 UnitedHealthcare Services Inc.\n1\nd. Patient is not receiving Livdelzi in combination with Iqirvo (elafibranor) or Ocaliva\n(obeticholic acid)\n-AND-\ne. Prescribed by one of the following:\n(1) Hepatologist\n(2) Gastroenterologist\nInitial authorization will be issued for 12 months\nB. Reauthorization\n1. Livdelzi will be approved based on all the following criteria:\na. Submission of medical records (e.g., laboratory values) documenting a reduction",
    "ion will be issued for 12 months\nB. Reauthorization\n1. Livdelzi will be approved based on all the following criteria:\na. Submission of medical records (e.g., laboratory values) documenting a reduction in\nALP level from pre-treatment baseline (i.e., prior to Livdelzi therapy)\n-AND-\nb. Patient does not have decompensated cirrhosis\n-AND-\nc. Patient is not receiving Livdelzi in combination with Iqirvo (elafibranor) or Ocaliva\n(obeticholic acid)\n-AND-\nd. Prescribed by one of the following:\n(1) Hepatologist\n(2) Gastroenterologist\nReauthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n^Tried/failed alternative(s) are supported by FDA labeling.\n3. Additional Clinical Rules:\n• Supply limits may be in place.\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2024 UnitedHealthcare Services Inc.\n2\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Livdelzi [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2024.\nProgram Prior Authorization/Medical Necessity – Livdelzi (seladelpar)\nChange Control\nDate Change\n12/2024 New program.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}